Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)With as few as two treatments per year, Susvimo may help people with DME maintain their visionApproval marks the second indication for Susvimo in addition to neovascular or ‘wet’ age-related macular degeneration (nAMD) Basel, 04 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvim ...